BTBP(SH:600161)2024-04-25 11:41Financial Performance - The company's operating revenue for Q1 2024 was CNY 1,221,955,159.91, representing a decrease of 5.42% compared to the same period last year[3]. - Net profit attributable to shareholders was CNY 316,673,978.07, an increase of 20.91% year-on-year[3]. - The net profit after deducting non-recurring gains and losses was CNY 313,481,082.28, reflecting a growth of 23.82% compared to the previous year[3]. - Basic earnings per share were CNY 0.19, up by 20.91% year-on-year[3]. - Net profit for Q1 2024 reached CNY 432,127,203.32, an increase of 20.4% from CNY 358,982,561.98 in Q1 2023[14]. - Total comprehensive income for the first quarter of 2024 reached ¥432,127,203.32, an increase from ¥358,982,561.98 in the same period of 2023, representing a growth of approximately 20.3%[15]. - Basic and diluted earnings per share for the first quarter of 2024 were both ¥0.19, up from ¥0.16 in the first quarter of 2023, indicating a 18.75% increase[15]. Cash Flow and Liquidity - The net cash flow from operating activities decreased by 24.47% to CNY 468,822,105.59[3]. - Net cash flow from operating activities for the first quarter of 2024 was ¥468,822,105.59, a decrease of 24.4% compared to ¥620,695,486.70 in the first quarter of 2023[20]. - Cash received from sales of goods and services was ¥1,348,247,790.31, down from ¥1,417,650,581.55 in the previous year, reflecting a decline of about 4.9%[17]. - The company reported a net cash outflow from investing activities of ¥783,213,723.82 in the first quarter of 2024, compared to a net outflow of ¥201,374,271.14 in the same period of 2023[20]. - The company's total operating cash outflow for the first quarter of 2024 was ¥917,791,804.00, an increase from ¥825,867,376.18 in the first quarter of 2023, reflecting a rise of about 11.1%[20]. - Cash and cash equivalents at the end of the first quarter of 2024 were ¥2,516,181,677.81, down from ¥2,607,475,607.64 at the end of the first quarter of 2023, a decrease of approximately 3.5%[20]. - The company reported a net cash outflow from investing activities of CNY -530,984,145.37 in Q1 2024, compared to a net inflow of CNY 130,561,428.59 in Q1 2023[29]. - Cash and cash equivalents at the end of Q1 2024 totaled CNY 1,235,145,691.04, down from CNY 1,574,677,634.17 at the beginning of the quarter[29]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 14,791,832,209.53, an increase of 4.26% from the end of the previous year[3]. - Total assets as of March 31, 2024, amounted to CNY 14,791,832,209.53, compared to CNY 14,188,056,936.91 at the end of 2023[10]. - Total liabilities increased to CNY 1,605,335,028.99 as of March 31, 2024, from CNY 1,433,686,959.69 at the end of 2023[11]. - The total liabilities and equity of the company as of Q1 2024 amounted to CNY 7,518,196,750.95, an increase from CNY 7,322,511,079.97 in the previous year[24]. - Total liabilities increased to ¥2,277,340,567.52 as of March 31, 2024, compared to ¥2,072,311,684.82 at the end of 2023, marking an increase of about 9.9%[23]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 48,217[6]. - The largest shareholder, China National Biotechnology Group Corporation, holds 45.64% of the shares[6]. - Shareholders' equity attributable to the parent company was CNY 10,139,253,146.61, up by 3.22% compared to the previous year[3]. - The total equity attributable to shareholders reached CNY 10,139,253,146.61 as of March 31, 2024, up from CNY 9,822,579,168.54 at the end of 2023[11]. - The company’s total equity remained stable at ¥5,240,856,183.43 as of March 31, 2024, compared to the previous period, indicating no significant changes in shareholder equity[23]. Expenses and Investments - Total operating costs for Q1 2024 were CNY 722,799,366.81, down 18.2% from CNY 883,395,917.16 in Q1 2023[13]. - Research and development expenses for Q1 2024 were CNY 24,452,750.69, significantly higher than CNY 9,539,026.33 in Q1 2023[14]. - The company incurred financial expenses of CNY -2,340,557.92 in Q1 2024, a significant decrease from CNY 734,344.11 in Q1 2023[25]. - The company reported investment income of CNY 10,234,166.63 in Q1 2024, up from CNY 8,437,500.00 in Q1 2023, representing an increase of about 21.3%[25]. - The company’s management expenses rose to CNY 24,025,374.33 in Q1 2024, compared to CNY 20,709,858.21 in Q1 2023, reflecting an increase of approximately 15.5%[25].